EE200300416A - Ravimvorm - Google Patents

Ravimvorm

Info

Publication number
EE200300416A
EE200300416A EEP200300416A EEP200300416A EE200300416A EE 200300416 A EE200300416 A EE 200300416A EE P200300416 A EEP200300416 A EE P200300416A EE P200300416 A EEP200300416 A EE P200300416A EE 200300416 A EE200300416 A EE 200300416A
Authority
EE
Estonia
Prior art keywords
pharmaceutical form
pharmaceutical
Prior art date
Application number
EEP200300416A
Other languages
English (en)
Estonian (et)
Inventor
Frances Bateman Nicola
Kay Cahill Julie
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0104749A external-priority patent/GB2372444A/en
Priority claimed from SE0102572A external-priority patent/SE0102572D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE200300416A publication Critical patent/EE200300416A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200300416A 2001-02-27 2002-02-22 Ravimvorm EE200300416A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0104749A GB2372444A (en) 2001-02-27 2001-02-27 A pharmaceutical formulation comprising bicalutamide and a hydroxypropylmethylcellulose polymer
SE0102572A SE0102572D0 (sv) 2001-07-19 2001-07-19 Pharmaceutical formulation
PCT/GB2002/000766 WO2002067893A2 (fr) 2001-02-27 2002-02-22 Preparation pharmaceutique

Publications (1)

Publication Number Publication Date
EE200300416A true EE200300416A (et) 2003-12-15

Family

ID=26245766

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300416A EE200300416A (et) 2001-02-27 2002-02-22 Ravimvorm

Country Status (22)

Country Link
US (1) US20040067257A1 (fr)
EP (1) EP1368001B1 (fr)
JP (2) JP3548566B2 (fr)
KR (1) KR20030077042A (fr)
CN (1) CN1503662A (fr)
AR (1) AR032912A1 (fr)
AT (1) ATE307571T1 (fr)
CA (1) CA2439366A1 (fr)
CZ (1) CZ20032225A3 (fr)
DE (1) DE60206889T2 (fr)
EE (1) EE200300416A (fr)
HU (1) HUP0302847A3 (fr)
IL (1) IL157389A0 (fr)
IS (1) IS6915A (fr)
MX (1) MXPA03007641A (fr)
NO (1) NO20033785L (fr)
NZ (1) NZ527532A (fr)
PL (1) PL365746A1 (fr)
RU (1) RU2003128971A (fr)
SK (1) SK10722003A3 (fr)
UY (1) UY27186A1 (fr)
WO (1) WO2002067893A2 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0103424D0 (sv) * 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
SE0103838D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
TWI355276B (en) * 2003-01-14 2012-01-01 Akira Tsuji Gastrointestinal absorption enhancer mediated by p
US20050008691A1 (en) * 2003-05-14 2005-01-13 Arturo Siles Ortega Bicalutamide compositions
WO2005074991A1 (fr) * 2004-02-09 2005-08-18 Kabushiki Kaisha Sangi Agent antitumoral
KR100539706B1 (ko) * 2005-01-25 2005-12-28 지엘팜텍 주식회사 타크로리무스 및 장용성 고분자를 함유하는 고체분산체
JP2008531531A (ja) * 2005-02-23 2008-08-14 アストラゼネカ アクチボラグ 方法
JP5097540B2 (ja) * 2005-04-06 2012-12-12 株式会社サンギ 腸管吸収用抗腫瘍剤
US7785629B2 (en) * 2005-06-21 2010-08-31 Helm Ag Bicalutamide-adsorbates, process for preparing same, and pharmaceutical compositions thereof
JP5052051B2 (ja) * 2006-06-16 2012-10-17 トーアエイヨー株式会社 腸溶性顆粒剤及びその製造方法
US20080045600A1 (en) * 2006-08-17 2008-02-21 Gawande Rahul S Bicalutamide compositions
WO2008063888A2 (fr) 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
JPWO2009038112A1 (ja) 2007-09-21 2011-01-06 塩野義製薬株式会社 Ｎｐｙｙ５受容体拮抗剤を含有する固形製剤
JP5204452B2 (ja) * 2007-10-02 2013-06-05 日医工株式会社 ビカルタミド含有製剤
EP2219624A2 (fr) * 2007-11-08 2010-08-25 Glaxo Group Limited Préparations pharmaceutiques
CN105237530A (zh) 2009-04-03 2016-01-13 豪夫迈罗氏公司 丙烷-1-磺酸{3-[5-(4-氯-苯基)-1H-吡咯并[2,3-b]吡啶-3-羰基]-2,4-二氟-苯基}-酰胺组合物及其用途
CN101987086B (zh) * 2009-08-03 2012-07-18 北京化工大学 一种超细比卡鲁胺口服片剂及其制备方法
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
WO2011057022A1 (fr) 2009-11-06 2011-05-12 Plexxikon, Inc. Composés et méthodes de modulation des kinases et leurs indications d'emploi
JP6109574B2 (ja) 2009-12-18 2017-04-05 カタラン、フランス、バインハイム、ソシエテ、アノニムＣａｔａｌｅｎｔ Ｆｒａｎｃｅ Ｂｅｉｎｈｅｉｍ Ｓａ 合成オリゴサッカリドを含有する医薬経口剤形
CN102525876B (zh) * 2010-12-15 2014-03-12 西安力邦医药科技有限责任公司 阿司匹林固体分散体、其制备方法、药物组合物和用途
CN102552103B (zh) * 2010-12-20 2013-11-20 西安力邦医药科技有限责任公司 拉米夫定固体分散体、其制备方法、药物组合物和用途
PT2672967T (pt) 2011-02-07 2018-12-07 Plexxikon Inc Compostos e métodos de modulação da quinase e suas indicações
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
CN109897004A (zh) 2012-09-11 2019-06-18 麦迪威森前列腺医疗有限责任公司 恩杂鲁胺制剂
JP2017523206A (ja) * 2014-08-07 2017-08-17 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ阻害剤の新規製剤
EP3226843B1 (fr) 2014-12-05 2021-05-26 Aragon Pharmaceuticals, Inc. Compositions anticancéreuses
CN109646404B (zh) * 2016-12-15 2022-10-04 华领医药技术（上海）有限公司 葡萄糖激酶激活剂的口服制剂及其制备方法
CA3134550A1 (fr) 2019-04-11 2020-10-15 R.P. Scherer Technologies, Llc Formulation pour administration orale de proteines, de peptides et de petites molecules a faible permeabilite
GB2584341B (en) 2019-05-31 2023-03-01 Gw Res Ltd Cannabinoid formulations
US11344526B2 (en) 2020-03-20 2022-05-31 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11173291B2 (en) * 2020-03-20 2021-11-16 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE28864T1 (de) * 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
AU1537292A (en) * 1991-04-16 1992-11-17 Nippon Shinyaku Co. Ltd. Method of manufacturing solid dispersion
EP0748220A4 (fr) * 1994-01-21 1997-09-10 Sepracor Inc Procedes et compositions de traitement de maladies dependantes des androgenes a l'aide de r-(-)-casodex optiquement pur
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
ATE324886T1 (de) * 2001-04-02 2006-06-15 Astrazeneca Ab Feste arzneizusammensetzung enthaltend 4'-cyano- trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy- 2-methylpropiono- m toluidide und pvp
SE0103424D0 (sv) * 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
SE0103839D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product

Also Published As

Publication number Publication date
CZ20032225A3 (cs) 2003-11-12
HUP0302847A2 (hu) 2003-12-29
EP1368001B1 (fr) 2005-10-26
CA2439366A1 (fr) 2002-09-06
IL157389A0 (en) 2004-05-12
EP1368001A2 (fr) 2003-12-10
NO20033785L (no) 2003-10-24
NO20033785D0 (no) 2003-08-26
SK10722003A3 (sk) 2004-02-03
DE60206889T2 (de) 2006-07-27
NZ527532A (en) 2004-12-24
IS6915A (is) 2003-08-15
JP3548566B2 (ja) 2004-07-28
JP2004143185A (ja) 2004-05-20
ATE307571T1 (de) 2005-11-15
DE60206889D1 (de) 2005-12-01
WO2002067893A3 (fr) 2003-01-16
HUP0302847A3 (en) 2005-05-30
AR032912A1 (es) 2003-12-03
KR20030077042A (ko) 2003-09-29
MXPA03007641A (es) 2003-12-04
CN1503662A (zh) 2004-06-09
JP2004521918A (ja) 2004-07-22
UY27186A1 (es) 2002-09-30
PL365746A1 (en) 2005-01-10
WO2002067893A2 (fr) 2002-09-06
RU2003128971A (ru) 2005-03-10
US20040067257A1 (en) 2004-04-08

Similar Documents

Publication Publication Date Title
EE200300416A (et) Ravimvorm
FI20011478A (fi) Farmaseuttinen koostumus
NO20033556L (no) Farmasöytiske formuleringer
NO20033384D0 (no) Farmasöytisk formulering
DE60204063D1 (de) Blisterverpackung
NO20035315D0 (no) Farmasöytiske kombinasjoner
NO20035627D0 (no) Farmasöytisk formulering
ATE335486T1 (de) Hydrazono-malonitrile
DE50209245D1 (de) Neuroprotektives medikament
FI20022128A (fi) Farmaseuttinen koostumus
ATE319694T1 (de) Phenylalkyne
ATA18372001A (de) Gelenksbolzenbaueinheit
ATA13992002A (de) Schlackengranulierungsanlage
FI20012242A0 (fi) Uudet farmaseuttiset yhdisteet
EE200300378A (et) Farmatseutiline kompositsioon
AT500276B8 (de) Radschwenksystem
ATA7462001A (de) Radspannwerk
SE0103116D0 (sv) Pharmaceutical combination
NO20041236L (no) Farmasoytisk formulering
FI5468U1 (fi) Farmaseuttinen koostumus
SE0102823D0 (sv) New drug
ATA6162001A (de) Schneekette
SE0101171D0 (sv) Pharmaceutical formulation
SE0102069D0 (sv) Pharmaceutical formulation
SE0102957D0 (sv) Pharmaceutical formulation